Lek Pharmaceuticals

Client:	Lek Pharmaceuticals
Representation:	Patent Litigation
Date:	2006-2007
Locations:	United States District Court for the Southern District of New York

Summary:

In the Omeprazole patent litigation Schiff Hardin represented Lek Pharmaceuticals, a subsidiary of Sandoz and Novartis, in its successful defense of AstraZeneca's patent infringement action regarding the plaintiff's Prilosec® product.

After a 42-day trial, in a 368-page opinion the Southern District of New York found that Lek's product did not infringe AstraZeneca's patent rights.

In re Omeprazole Patent Litigation (490 F.Supp.2d 381)

Attorney Advertising Notice

Schiff Hardin LLP is a general practice law firm representing clients across the United States and around the world. We have nearly 400 attorneys in offices located in Atlanta, Boston, Chicago, Lake Forest, New York, San Francisco and Washington. Our attorneys are strong advocates and trusted advisers — roles that contribute to many lasting client relationships.